Dear Newron Shareholder,
when presenting our Annual Report 2023, recently, we looked back at the significant progress Newron has made, last year: against a backdrop of challenging
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after
Ad hoc announcement pursuant to Art. 53 LR
Proceeds of up to EUR 15.0* million
Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or
Ad hoc announcement pursuant to Art. 53 LR
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
